Medical Device | February 23, 2022
Medtronic receives USFDA approval for InterStim X system to manage bladder and bowel control
New InterStim X system provides 10 to 15 years of battery life without the need to recharge
New InterStim X system provides 10 to 15 years of battery life without the need to recharge
he financing was significantly oversubscribed with high demand from both existing and new investors.
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
Subscribe To Our Newsletter & Stay Updated
